Review




Structured Review

Aquarray GmbH droplet microarray slide
Droplet Microarray Slide, supplied by Aquarray GmbH, used in various techniques. Bioz Stars score: 90/100, based on 1 PubMed citations. ZERO BIAS - scores, article reviews, protocol conditions and more
https://www.bioz.com/result/droplet microarray slide/product/Aquarray GmbH
Average 90 stars, based on 1 article reviews
droplet microarray slide - by Bioz Stars, 2026-03
90/100 stars

Images



Similar Products

90
Aquarray GmbH droplet microarray slide
Droplet Microarray Slide, supplied by Aquarray GmbH, used in various techniques. Bioz Stars score: 90/100, based on 1 PubMed citations. ZERO BIAS - scores, article reviews, protocol conditions and more
https://www.bioz.com/result/droplet microarray slide/product/Aquarray GmbH
Average 90 stars, based on 1 article reviews
droplet microarray slide - by Bioz Stars, 2026-03
90/100 stars
  Buy from Supplier

90
Aquarray GmbH droplet microarray dma slides
Droplet Microarray Dma Slides, supplied by Aquarray GmbH, used in various techniques. Bioz Stars score: 90/100, based on 1 PubMed citations. ZERO BIAS - scores, article reviews, protocol conditions and more
https://www.bioz.com/result/droplet microarray dma slides/product/Aquarray GmbH
Average 90 stars, based on 1 article reviews
droplet microarray dma slides - by Bioz Stars, 2026-03
90/100 stars
  Buy from Supplier

90
Aquarray GmbH droplet microarray (dma) slides
Workflow for high‐throughput drug screening and hit validation. The droplet <t>microarray</t> chip uses minimal reagents (200 nL medium, 300 cells per spot) to screen 2208 FDA‐approved drugs rapidly and economically. The assay is validated using MTT assays in a standard 96‐well plate. On‐ and off‐target effects are assessed using Western blot and mass spectrometry. Drug target analysis is correlated with patient survival data from the Cancer Genome Atlas (TCGA) and the Chinese Glioma Genome Atlas (CGGA) databases to facilitate personalized clinical treatment.
Droplet Microarray (Dma) Slides, supplied by Aquarray GmbH, used in various techniques. Bioz Stars score: 90/100, based on 1 PubMed citations. ZERO BIAS - scores, article reviews, protocol conditions and more
https://www.bioz.com/result/droplet microarray (dma) slides/product/Aquarray GmbH
Average 90 stars, based on 1 article reviews
droplet microarray (dma) slides - by Bioz Stars, 2026-03
90/100 stars
  Buy from Supplier

90
Aquarray GmbH customized droplet microarray slides
Workflow for high‐throughput drug screening and hit validation. The droplet <t>microarray</t> chip uses minimal reagents (200 nL medium, 300 cells per spot) to screen 2208 FDA‐approved drugs rapidly and economically. The assay is validated using MTT assays in a standard 96‐well plate. On‐ and off‐target effects are assessed using Western blot and mass spectrometry. Drug target analysis is correlated with patient survival data from the Cancer Genome Atlas (TCGA) and the Chinese Glioma Genome Atlas (CGGA) databases to facilitate personalized clinical treatment.
Customized Droplet Microarray Slides, supplied by Aquarray GmbH, used in various techniques. Bioz Stars score: 90/100, based on 1 PubMed citations. ZERO BIAS - scores, article reviews, protocol conditions and more
https://www.bioz.com/result/customized droplet microarray slides/product/Aquarray GmbH
Average 90 stars, based on 1 article reviews
customized droplet microarray slides - by Bioz Stars, 2026-03
90/100 stars
  Buy from Supplier

90
Aquarray GmbH droplet-microarray (dma) slides (1 × spots)
Workflow for high‐throughput drug screening and hit validation. The droplet <t>microarray</t> chip uses minimal reagents (200 nL medium, 300 cells per spot) to screen 2208 FDA‐approved drugs rapidly and economically. The assay is validated using MTT assays in a standard 96‐well plate. On‐ and off‐target effects are assessed using Western blot and mass spectrometry. Drug target analysis is correlated with patient survival data from the Cancer Genome Atlas (TCGA) and the Chinese Glioma Genome Atlas (CGGA) databases to facilitate personalized clinical treatment.
Droplet Microarray (Dma) Slides (1 × Spots), supplied by Aquarray GmbH, used in various techniques. Bioz Stars score: 90/100, based on 1 PubMed citations. ZERO BIAS - scores, article reviews, protocol conditions and more
https://www.bioz.com/result/droplet-microarray (dma) slides (1 × spots)/product/Aquarray GmbH
Average 90 stars, based on 1 article reviews
droplet-microarray (dma) slides (1 × spots) - by Bioz Stars, 2026-03
90/100 stars
  Buy from Supplier

90
Aquarray GmbH droplet-microarray (dma) slides × spots
Workflow for high‐throughput drug screening and hit validation. The droplet <t>microarray</t> chip uses minimal reagents (200 nL medium, 300 cells per spot) to screen 2208 FDA‐approved drugs rapidly and economically. The assay is validated using MTT assays in a standard 96‐well plate. On‐ and off‐target effects are assessed using Western blot and mass spectrometry. Drug target analysis is correlated with patient survival data from the Cancer Genome Atlas (TCGA) and the Chinese Glioma Genome Atlas (CGGA) databases to facilitate personalized clinical treatment.
Droplet Microarray (Dma) Slides × Spots, supplied by Aquarray GmbH, used in various techniques. Bioz Stars score: 90/100, based on 1 PubMed citations. ZERO BIAS - scores, article reviews, protocol conditions and more
https://www.bioz.com/result/droplet-microarray (dma) slides × spots/product/Aquarray GmbH
Average 90 stars, based on 1 article reviews
droplet-microarray (dma) slides × spots - by Bioz Stars, 2026-03
90/100 stars
  Buy from Supplier

Image Search Results


Workflow for high‐throughput drug screening and hit validation. The droplet microarray chip uses minimal reagents (200 nL medium, 300 cells per spot) to screen 2208 FDA‐approved drugs rapidly and economically. The assay is validated using MTT assays in a standard 96‐well plate. On‐ and off‐target effects are assessed using Western blot and mass spectrometry. Drug target analysis is correlated with patient survival data from the Cancer Genome Atlas (TCGA) and the Chinese Glioma Genome Atlas (CGGA) databases to facilitate personalized clinical treatment.

Journal: Advanced Healthcare Materials

Article Title: Repurposing FDA‐Approved Drugs for Temozolomide‐Resistant IDH1 Mutant Glioma Using High‐Throughput Miniaturized Screening on Droplet Microarray Chip

doi: 10.1002/adhm.202300591

Figure Lengend Snippet: Workflow for high‐throughput drug screening and hit validation. The droplet microarray chip uses minimal reagents (200 nL medium, 300 cells per spot) to screen 2208 FDA‐approved drugs rapidly and economically. The assay is validated using MTT assays in a standard 96‐well plate. On‐ and off‐target effects are assessed using Western blot and mass spectrometry. Drug target analysis is correlated with patient survival data from the Cancer Genome Atlas (TCGA) and the Chinese Glioma Genome Atlas (CGGA) databases to facilitate personalized clinical treatment.

Article Snippet: The droplet microarray (DMA) slides were purchased from Aquarray GmbH (catalog, IR0050241542, Eggenstein‐Leopoldshafen, Germany).

Techniques: High Throughput Screening Assay, Drug discovery, Biomarker Discovery, Microarray, Western Blot, Mass Spectrometry